549 Efficacy of interferon (standard or pegylated) plus ribavirin in navie patients with hepatitis c virus genotype 5. A French national study

2005 ◽  
Vol 42 ◽  
pp. 200
2005 ◽  
Vol 50 (12) ◽  
pp. 2348-2351 ◽  
Author(s):  
Jean Delwaide ◽  
Christiane Gerard ◽  
Catherine Reenaers ◽  
Dolores Vaira ◽  
Boris Bastens ◽  
...  

2011 ◽  
Vol 1 (2) ◽  
pp. 28
Author(s):  
Emanuele Durante-Mangoni ◽  
Domenico Iossa ◽  
Umberto Malgeri

Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory changes and advanced liver fibrosis. The patient had a high viral load but a small serum level of hepatitis C core antigen. On combination antiviral treatment with pegylated-interferon alpha 2a, 180 ?g/week, and ribavirin, 1200 mg/day, the patient experienced an impressive reduction in serum HCV RNA as early as day 2 of treatment and eventually became a sustained virological responder. Our viral kinetics data support previous clinical studies showing HCV genotype 5 could be as intrinsically sensitive to interferon as HCV genotypes 2 and 3.


2008 ◽  
Vol 15 (5) ◽  
pp. 383-386 ◽  
Author(s):  
N. Antaki ◽  
A. Hermes ◽  
M. Hadad ◽  
M. Ftayeh ◽  
F. Antaki ◽  
...  

2012 ◽  
Vol 18 (3) ◽  
pp. 263-269 ◽  
Author(s):  
Nabil Antaki ◽  
Dirar Abboud ◽  
Fadi Antaki ◽  
Antonio Craxi

2014 ◽  
Vol 48 (2) ◽  
pp. 160-165 ◽  
Author(s):  
Vasilios Papastergiou ◽  
Labrini Skorda ◽  
Philippos Lisgos ◽  
Maria Stampori ◽  
Georgios Ntetskas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document